KPWS
CRSP icon

Kestra Private Wealth Services’s CRISPR Therapeutics CRSP Stock Holding History

Kestra Private Wealth Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$576K Sell
10,555
-509
-5% -$26.8K 0.01% 1160
2026
Q1 		$526K Sell
11,064
-394
-3% -$20.8K 0.01% 1171
2025
Q4 		$601K Buy
11,458
+1,250
+12% +$74.9K 0.01% 1064
2025
Q3 		$662K Sell
10,208
-666
-6% -$38.2K 0.01% 964
2025
Q2 		$529K Sell
10,874
-11,117
-51% -$430K 0.01% 1011
2025
Q1 		$748K Buy
21,991
+1,355
+7% +$57.4K 0.01% 790
2024
Q4 		$812K Buy
20,636
+310
+2% +$14.6K 0.01% 727
2024
Q3 		$955K Buy
20,326
+4,408
+28% +$224K 0.02% 627
2024
Q2 		$860K Buy
+15,918
New +$921K 0.02% 627

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Kestra Private Wealth Services's CRSP Position: Q2 2026 in Review

Kestra Private Wealth Services reduced its CRISPR Therapeutics (CRSP) stake by 4.6% in Q2 2026, selling an estimated $26.8K and leaving 10,555 shares worth $576K. The position accounts for 0.01% of the portfolio, ranked #1160.

Kestra Private Wealth Services first reported a position in CRSP in Q2 2024 and has held it in 9 quarters since. The position peaked at $955K in Q3 2024. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Kestra Private Wealth Services held 10,555 shares of CRISPR Therapeutics worth $576K as of Q2 2026.
  • Kestra Private Wealth Services sold 509 CRISPR Therapeutics shares in Q2 2026, an estimated $26.8K.
  • CRISPR Therapeutics made up 0.01% of Kestra Private Wealth Services's portfolio in Q2 2026, its #1160 holding.
  • Kestra Private Wealth Services first reported a position in CRISPR Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Kestra Private Wealth Services's CRISPR Therapeutics position peaked at $955K in Q3 2024.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Kestra Private Wealth Services's 13F filing for Q2 2026, filed 28 Jul 2026.